Registry Study on Rare Cancers in Korea

NCT ID: NCT06746766

Last Updated: 2024-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-18

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine the participation rate of patients with registered rare cancers in clinical research.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data collection includes:

* Clinical characteristics (diagnosis, treatment information, primary/metastatic sites, staging, gender/age)
* Survival information (diagnosis date, recurrence date, death date, disease progression)
* Pathological information (diagnosis, genomic information)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rare Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rare Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged ≥19 years
* Confirmed rare cancer
* Life expectancy ≥3 months

Exclusion Criteria

-Serious or unstable medical/psychiatric conditions
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hyo Song Kim

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hyo Song Kim, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Yonsei Cencer center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Severance Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hyo Song Kim, MD, Ph.D

Role: CONTACT

Phone: 82-2-2228-8124

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Gatta G, Capocaccia R, Trama A, Martinez-Garcia C; RARECARE Working Group. The burden of rare cancers in Europe. Adv Exp Med Biol. 2010;686:285-303. doi: 10.1007/978-90-481-9485-8_17.

Reference Type BACKGROUND
PMID: 20824452 (View on PubMed)

Very rare cancers--a problem neglected. Lancet Oncol. 2001 Apr;2(4):189. doi: 10.1016/s1470-2045(00)00273-4. No abstract available.

Reference Type BACKGROUND
PMID: 11905758 (View on PubMed)

Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer. 2006 Sep;42(13):2183-90. doi: 10.1016/j.ejca.2006.06.006.

Reference Type BACKGROUND
PMID: 16919780 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2024-1207

Identifier Type: OTHER

Identifier Source: secondary_id

4-2024-1207

Identifier Type: -

Identifier Source: org_study_id